The New England journal of medicine
-
Randomized Controlled Trial
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children. ⋯ A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).